Wedmont Private Capital Invests $361,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Wedmont Private Capital bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,644 shares of the medical research company’s stock, valued at approximately $361,000.

Other hedge funds have also modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Charles River Laboratories International by 417.3% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,288 shares of the medical research company’s stock worth $253,000 after acquiring an additional 1,039 shares during the last quarter. Mawer Investment Management Ltd. lifted its holdings in shares of Charles River Laboratories International by 49.4% during the second quarter. Mawer Investment Management Ltd. now owns 8,923 shares of the medical research company’s stock worth $1,909,000 after purchasing an additional 2,951 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Charles River Laboratories International by 9.3% during the second quarter. Federated Hermes Inc. now owns 212,868 shares of the medical research company’s stock worth $45,547,000 after purchasing an additional 18,196 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in shares of Charles River Laboratories International by 1.5% during the third quarter. CIBC Private Wealth Group LLC now owns 103,472 shares of the medical research company’s stock worth $20,364,000 after purchasing an additional 1,539 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Charles River Laboratories International by 7.2% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 9,148 shares of the medical research company’s stock worth $1,801,000 after purchasing an additional 613 shares during the period. 97.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Jefferies Financial Group downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, January 12th. StockNews.com assumed coverage on Charles River Laboratories International in a report on Thursday. They set a “hold” rating for the company. Guggenheim raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $255.00 price target for the company in a report on Thursday, February 23rd. Robert W. Baird increased their price target on Charles River Laboratories International from $275.00 to $285.00 and gave the stock an “outperform” rating in a report on Wednesday, January 11th. Finally, Citigroup reduced their target price on Charles River Laboratories International from $280.00 to $260.00 and set a “buy” rating for the company in a report on Thursday, February 23rd. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $270.83.

Insider Buying and Selling

In related news, CEO James C. Foster sold 20,000 shares of Charles River Laboratories International stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $250.00, for a total transaction of $5,000,000.00. Following the completion of the sale, the chief executive officer now owns 216,594 shares in the company, valued at approximately $54,148,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Shannon M. Parisotto sold 4,558 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $254.41, for a total transaction of $1,159,600.78. Following the completion of the sale, the executive vice president now owns 6,010 shares in the company, valued at approximately $1,529,004.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO James C. Foster sold 20,000 shares of Charles River Laboratories International stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $250.00, for a total value of $5,000,000.00. Following the sale, the chief executive officer now owns 216,594 shares of the company’s stock, valued at approximately $54,148,500. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,763 shares of company stock worth $6,974,921. 1.10% of the stock is owned by corporate insiders.

Charles River Laboratories International Trading Down 0.3 %

Shares of CRL stock opened at $192.92 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $181.36 and a fifty-two week high of $308.15. The stock has a market cap of $9.84 billion, a P/E ratio of 20.37, a P/E/G ratio of 1.36 and a beta of 1.36. The business has a fifty day simple moving average of $233.82 and a 200-day simple moving average of $220.85. The company has a quick ratio of 1.08, a current ratio of 1.32 and a debt-to-equity ratio of 0.91.

Charles River Laboratories International (NYSE:CRL – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The medical research company reported $2.98 earnings per share for the quarter, beating analysts’ consensus estimates of $2.75 by $0.23. Charles River Laboratories International had a return on equity of 20.98% and a net margin of 12.23%. The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the business posted $2.49 earnings per share. The business’s revenue for the quarter was up 21.5% on a year-over-year basis. On average, analysts forecast that Charles River Laboratories International, Inc. will post 10.25 earnings per share for the current fiscal year.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.